Bridgebio Oncology Therapeutics, Inc. (BBOT)
1.85
-0.01
(-0.54%)
USD |
NASDAQ |
Nov 20, 09:38
Bridgebio Oncology Therapeutics Enterprise Value : -42.25M for Nov. 19, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 19, 2026 | -42.25M |
| November 18, 2026 | -46.66M |
| November 17, 2026 | -35.83M |
| November 16, 2026 | -32.62M |
| November 13, 2026 | -19.79M |
| November 12, 2026 | -2.937M |
| November 11, 2026 | 13.91M |
| November 10, 2026 | -14.97M |
| November 09, 2026 | -6.948M |
| November 06, 2026 | -27.81M |
| November 05, 2026 | -17.38M |
| November 04, 2026 | -6.948M |
| November 03, 2026 | -5.344M |
| November 02, 2026 | -6.146M |
| October 30, 2026 | 18.73M |
| October 29, 2026 | 25.15M |
| October 28, 2026 | 33.17M |
| October 27, 2026 | 24.34M |
| October 26, 2026 | 20.33M |
| October 23, 2026 | 21.94M |
| October 22, 2026 | 37.18M |
| October 21, 2026 | 23.54M |
| October 20, 2026 | 26.75M |
| October 19, 2026 | 37.18M |
| October 16, 2026 | 34.77M |
| Date | Value |
|---|---|
| October 15, 2026 | 45.20M |
| October 14, 2026 | 41.59M |
| October 13, 2026 | 45.20M |
| October 12, 2026 | 70.08M |
| October 09, 2026 | 74.09M |
| October 08, 2026 | 82.91M |
| October 07, 2026 | 84.52M |
| October 06, 2026 | 89.33M |
| October 05, 2026 | 97.36M |
| October 02, 2026 | 120.62M |
| October 01, 2026 | 124.64M |
| September 30, 2026 | 137.47M |
| September 29, 2026 | 90.85M |
| September 28, 2026 | 82.04M |
| September 25, 2026 | 93.26M |
| September 24, 2026 | 96.46M |
| September 23, 2026 | 110.08M |
| September 22, 2026 | 150.14M |
| September 21, 2026 | 150.14M |
| September 18, 2026 | 158.95M |
| September 17, 2026 | 168.57M |
| September 16, 2026 | 158.15M |
| September 15, 2026 | 167.76M |
| September 14, 2026 | 181.38M |
| September 11, 2026 | 173.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 1.184B |
| IRulya Therapeutics, Inc. | 79.19M |
| PepGen Inc. | 183.00M |
| Q32 Bio, Inc. | -30.98M |
| Oncolytics Biotech, Inc. | 49.62M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.18M |
| Total Expenses (Quarterly) | 34.18M |
| EPS Diluted (Quarterly) | -0.4262 |
| Earnings Yield | -66.61K% |
| Normalized Earnings Yield | -66606.75 |